



Redefine What's Possible Across R&D With Digital and AI-Driven Pathology


The enterprise pathology platform where biomarker teams discover, development teams execute, and data compounds into your competitive advantage








Introduction

Pathology now drives the highest-stakes decisions in drug development – from target selection to patient enrollment to the biomarkers that define a program’s success. It deserves technology that doesn’t just keep up, but amplifies its impact.

Concentriq® LS delivers. It’s where scientists interrogate tissue to understand disease, where development teams drive clinical trials forward, and where every study builds a cross-program intelligence foundation that compounds into a lasting organizational advantage.



-  **The only platform architected for the full pathology AI lifecycle** – centralize images from internal labs, CRO partners, and Proscia’s real-world data, build and run AI models with foundation model APIs and a fully managed compute service, and extend into clinical deployment right on Concentriq when your organization is ready
-  **AI that meets your science today and grows with it tomorrow** – 120+ applications deployable directly in the Concentriq viewer, and infrastructure to develop and scale proprietary models
-  **Cross-program intelligence foundation enriched with every study** – research scientists, clinical pathologists, AI engineers, and CRO partners work from a single shared data asset, building reusable libraries of images, annotations, and AI results that give study teams cross-stage context from discovery through development and fuel proprietary AI
-  **GxP-ready compliance infrastructure** – retain control over data, models, and infrastructure while operating in regulated research workflows. Learn how we support GxP compliance.
-  **Enterprise-grade scalability** – built for organizations processing hundreds of thousands of slides per year across global sites

[VIEW WHITE PAPER](#) →

16

of the top 20 pharma rely on Concentriq LS

40%


Reduction in time spent searching for data¹

60%

Accelerated workflow cycles, speeding time to market²

13x

Faster AI development³



¹ Based on customer-reported results at a leading global CRO

² Based on customer-reported results at a leading global CRO

³ Chivers C, Spurrier V, Toulgaridis K, Baatz J, Ianni J. Concentriq Embeddings Accelerated Biomarker Prediction AI Development by 13x: How Proscia’s AI R&D Team Leveraged Foundation Models at Scale to Build 80 Breast Cancer Biomarker Prediction Models in Under 24 Hours. Proscia; 2024. <https://go.proscia.com/case-study-embeddings>

Capabilities Designed for the Complexity and Speed of Modern Pathology

AI-Driven Image Analysis

Accelerate biomarker identification, de-risk cohort selection, and enrich trial populations by deploying the right AI application for your science – whether third-party or proprietary, all from one consistent viewer interface. Launch analysis directly on slides with results displayed as editable annotations for immediate interpretation.

Whether the need is multiplex exploratory research, quantification for strategic patient and sample selection, or biomarker enrichment for targeted patient stratification, teams work with best-in-class tools purpose-matched to their scientific workflows.



Intuitive High-Performance Review & Annotation

Annotate brightfield, fluorescence, and z-stack images with brush, magnetic brush, and automated shape detection tools. Because data preparation, image review, annotation, and AI analysis all occur without leaving the platform, teams eliminate the handoffs and file transfers that add weeks to study timelines. Every annotation is audit-trailed.




PRECISION MEDICINE AI PORTFOLIO: EXAMPLE USE CASES

Applications from leading AI vendors across a wide range of tissue types are seamlessly deployed from Concentriq directly into workflows.

120+ APPS SPANNING DISCOVERY TO CLINICAL DEVELOPMENT


EXPLORATORY RESEARCH




IF Multiplex, Lung Cancer TME



Dual RNAscope, HCC




IF mCherry+GFP, Axon Density




IF Multiplex, Breast Cancer TME


STRATEGIC PATIENT & SAMPLE SELECTION




Automated QC



H&E Nuclei Detection




H&E Liver Steatosis Quantification




H&E Tumor Load Quantification


TARGETED PATIENT STRATIFICATION




H&E Biomarker Enrichment



H&E Breast Risk Profiling



Colorectal Predictive Biomarker



Pre-Screening MSS Colorectal

Real-Time Global Collaboration

Reach diagnostic consensus across global trial sites and CRO partners in real time. Pathologists review, annotate, and adjudicate simultaneously in live sessions – replacing sequential handoffs with synchronized alignment that accelerates enrollment decisions.

Configurable, Study-Ready Workflows

Launch studies faster and standardize execution across sites and sponsors, without sacrificing consistency or compliance. Configure study templates that encode critical assessment parameters, and onboard new trial sites onto proven workflows without retraining as programs scale globally.

A Living Data Asset That Grows With Every Study

Every study, annotation, and AI result enriches a unified data asset spanning sites, scanners, and partners – queryable by study ID, biomarker, tissue type, or custom metadata so scientists can explore phenotypes, compare cohorts, and layer AI analyses to refine hypotheses in real time.

Archived H&E slides transform into in silico omics assays for cohort enrichment or retrospective signal validation, all without costly sequencing.

Leading Interoperability – No Vendor Lock-In


An open, interoperable architecture integrates with leading scanners, LIMS, and image analysis applications. Native support for all major scanner formats eliminates ingestion friction, bi-directional LIMS integration keeps data synchronized, RESTful APIs give development teams the flexibility to build custom workflows. As new tools emerge, your platform evolves with them.

EXAMPLE

Your team is characterizing 25,000 archival bladder cancer samples for FGFR mutation. Triage based on an AI-derived biomarker could reduce unnecessary NGS testing by 20% while preserving sensitivity.⁴ This could generate \$25 million⁵ in cost savings from genomic testing alone, before accounting for additional savings from high-cost assays like IHC across other disease areas.

“Digitization is future-proofing. Keeping all our whole slide images centralized in the cloud means they’ll be ready when we want to hunt for the next AI biomarker. Our own clinical data can be the best fuel for discoveries we haven’t even imagined yet.”

DIGITAL & DATA STRATEGY LEAD
TOP 50 PHARMA
PROSCIA MARKET RESEARCH (2025)



4 Juan Ramon A, Parmar C, Carrasco-Zevallos OM, et al. Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial. Nat Commun. 2024;15(1):4690. Published 2024 Jun 1. doi:10.1038/s41467-024-49153-9

5 Assuming a cost of \$5,000 per test per Vanderpoel, J. et al. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer. J. Med. Econ. 25, 457–468 (2022).

Your AI – Built and Deployed at Enterprise Scale

Proscia fills critical data gaps and provides data science teams with the infrastructure to develop custom AI models and deploy them directly into routine scientific workflows – without provisioning servers, managing infrastructure, or moving data off-platform. Teams retain full IP ownership of their models, and all data remains within a secure, regulated environment.

Concentriq Compute gets your AI models from ready to running in days. It's a fully managed compute service that eliminates the infrastructure bottleneck. Just give us your model as a containerized workload. We'll run it for you alongside Concentriq, and scale it up as needed. And your data stays secure: no data exports, duplication, or transfers.



MULTIMODAL REAL-WORLD DATA

Train and validate AI models.

Access whole slide images linked to clinical, molecular, and genomic context to augment controlled clinical trial data and support the development of high-performing, clinically viable AI models.



CONCENTRIQ EMBEDDINGS

Accelerate model building.

Generate embeddings from state-of-the-art foundation models directly in Concentriq LS to expedite AI model development 13x faster than traditional approaches.



CONCENTRIQ COMPUTE

Deploy and scale instantly.

Run proprietary and open source AI models directly where your data lives and get your AI models from ready to running in days. Retain full IP ownership and automatically scale pilot workloads to large studies – without provisioning servers or managing infrastructure.

Proven Impact Across the R&D Pipeline

Together, Concentriq LS and Concentriq AP-Dx serve as the central infrastructure for pathology across the drug development lifecycle.



CONCENTRIQ LS

AI
REAL-WORLD DATA

CONCENTRIQ AP-Dx

DISCOVERY

Efficiently identify, explore, & mature high-quality candidates.

PRECLINICAL DEVELOPMENT

Get to clinical trial faster, with more confidence.

EARLY CLINICAL DEVELOPMENT

Shorten project timelines & maximize success.

LATE CLINICAL DEVELOPMENT

Streamline clinical trials across global sites & teams.

DIAGNOSTICS

Accelerate market entry & reach more patients.

DISCOVERY & TRANSLATIONAL RESEARCH

Expanding into Discovery-Stage Spatial Biology Services

The Challenge: A global CRO was losing discovery-stage spatial biology projects because its homegrown image management system, could not support multiplex immunofluorescence or the AI-driven image analysis sponsors required for tumor microenvironment characterization. Clients seeking spatial context for biomarker strategy and patient selection were taking their entire book of work to competitors who could serve as a one-stop partner.

The Solution: The CRO standardized on Concentriq LS as its enterprise pathology platform, deploying its integrated AI ecosystem and native support for multiplex immunofluorescence workflows to launch discovery-stage spatial biology services alongside existing clinical trial pathology. The platform's universal scanner format ingestion and cloud-based deployment enabled seamless data sharing with sponsors, while GxP-ready compliance infrastructure supported regulated work from day one.

The Outcome: The CRO is now working on capturing projects it had previously been unable to bid on. Concentriq LS replaced the legacy homegrown system across five global sites, harmonizing operations under a single set of SOPs while eliminating the IT overhead of maintaining custom software.

PRECLINICAL DEVELOPMENT

Unifying Toxicologic Pathology Across Discovery and Development

The Challenge: A global biopharma company processing over 2,000 toxicologic pathology slides per month relied on fragmented technology stacks, and proprietary software to capture and store images. CRO partners shared data via FTP sites or shipped hard drives, making image access cumbersome, peer review impossible, and data exchange expensive and risky.

The Solution: The company deployed Concentriq LS as its end-to-end enterprise pathology platform, integrating with existing scanners, image analysis tools, and LIMS so internal teams and CRO partners could scan, review, analyze, and collaborate in a single regulated environment.

The Outcome: Pathologists work from a single platform across discovery through clinical trials, with integrated AI image analysis capabilities that let scientists generate analyses, collaborate on peer review, and build proprietary image-based biomarkers on the centralized data foundation.



CLINICAL DEVELOPMENT

Standardizing Pathology Review Across Global Clinical Trial Sites

The Challenge: IQVIA Laboratories manages clinical trials across dozens of pathologists worldwide, where sub-specialists must review the same cases across time zones while maintaining standardized, reproducible assessments at scale. Adding to this complexity, each pharma sponsor brings unique requirements for image analysis and reporting — demanding consistency without compromising the flexibility individual programs require.

The Solution: IQVIA deployed Concentriq to centralize slide scanning, image management, and pathologist review into a single digital workflow accessible globally, enabling real-time collaboration and sub-specialist consultations without shipping physical slides. The platform’s open architecture integrated with multiple image analysis vendors to meet sponsor-specific needs, while standardized workflows, comprehensive audit trails, and role-based access controls supported regulatory requirements.

The Outcome: Pathologists across the globe now review, collaborate, and reach consensus on cases as if operating from a single location, dramatically reducing turnaround times and enabling faster patient enrollment. The standardized digital workflow improved diagnostic reproducibility, simplified regulatory compliance, and gave sponsors confidence in consistent assessments across all trial sites.

“Standardization [on Concentriq] aids in patient enrollment in clinical trials, stratification, randomization into treatment arms and endpoint evaluation.”

DR. AMANDA HEMMERICH
GLOBAL DIRECTOR OF DIGITAL
PATHOLOGY INNOVATION AT IQVIA

Secure, Compliant, and Proven to Scale

Enterprise-grade infrastructure that fits your environment, connects your systems, and grows with your organization.

Cloud-Native, Enterprise-Ready

Deploy Concentriq LS as a fully managed cloud infrastructure purpose-built for the scale and complexity of enterprise pathology. Proscia eliminates infrastructure management overhead so IT teams can focus on enabling science, not maintaining servers.

Trusted by the Most Regulated Organizations

Concentriq LS is designed to meet the security, governance, and compliance demands of regulated life sciences environments. SOC 2 Type II certification, end-to-end encryption, SAML 2.0 SSO, and granular role-based access controls protect data at every layer, while comprehensive audit logs and traceability ensure your teams are always audit-ready across HIPAA, GDPR, and GxP frameworks.

A Trusted Partner that Accelerates Time to Value

Proscia's professional services team combines deep scientific domain expertise with enterprise implementation best practices — acting as a trusted advisor from pre-implementation planning through enterprise-wide scale. A dedicated project manager leads every engagement, guiding systems analysis, solution design, data migration, validation support, and end-user training. The relationship doesn't end at go-live: ongoing customer success management and technical support ensures your organization continuously gets more value from the platform as your programs evolve.

Trusted by Industry Leaders

Leading research organizations, including 16 of the top 20 pharmaceutical companies, trust Concentriq LS to accelerate discovery. Some of our partners include:



“We’re no longer talking about potential. We’re talking about real tangible impact. We’re seeing firsthand how computational pathology on Concentriq is influencing early decision making, biomarker strategy, and even clinical trial design.”

**COMPUTATIONAL BIOLOGY AND
BIOMARKER DISCOVERY LEADER
TOP 20 PHARMACEUTICAL COMPANY**





Get Started

Proscia is changing the way the world practices pathology to transform cancer research and diagnosis. Discover how Concentriq LS can accelerate your therapeutic development programs.

Connect with us today to schedule a personalized demo from a life sciences digital pathology expert.

proscia.com/contact



**2026
BEST IN KLAS**

**RATED #1
BY CUSTOMERS**

© Copyright 2026. Proscia Inc. Proscia, Concentriq, Proscia Aperture, the circles logo and Proscia Aperture logo are trademarks or registered trademarks owned by Proscia Inc. All rights reserved.

Concentriq AP-Dx is FDA-cleared for primary diagnosis in the United States (U.S.) with the Hamamatsu NanoZoomer® S360MD Slide scanner and is licensed in Canada and CE-marked under the EU IVDR for primary diagnosis. Concentriq AP-Dx is not intended for use with frozen sections, cytology, or non-FPPE hematopathology specimens. Concentriq AP and Concentriq LS are for Research Use Only. Not for use in diagnostic procedures. Proscia's AI applications are available for research use only.